Pacific Biosciences of California
$ 1.66
5.06%
24 Feb - close price
- Market Cap 477,014,000 USD
- Current Price $ 1.66
- High / Low $ 1.70 / 1.57
- Stock P/E N/A
- Book Value 0.02
- EPS -1.82
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.34 %
- ROE -2.13 %
- 52 Week High 2.73
- 52 Week Low 0.85
About
Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to solve genetically complex problems. The company is headquartered in Menlo Park, California.
Analyst Target Price
$2.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-12 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-13 | 2024-11-07 | 2024-08-07 | 2024-05-09 | 2024-02-15 | 2023-10-30 | 2023-08-02 | 2023-05-02 |
| Reported EPS | -0.12 | -0.12 | -0.13 | -0.15 | -0.2 | -0.17 | -0.64 | -0.29 | -0.31 | -0.26 | -0.28 | -0.36 |
| Estimated EPS | -0.1466 | -0.14 | -0.17 | -0.19 | -0.17 | -0.21 | -0.23 | -0.28 | -0.29 | -0.33 | -0.32 | -0.33 |
| Surprise | 0.0266 | 0.02 | 0.04 | 0.04 | -0.03 | 0.04 | -0.41 | -0.01 | -0.02 | 0.07 | 0.04 | -0.03 |
| Surprise Percentage | 18.1446% | 14.2857% | 23.5294% | 21.0526% | -17.6471% | 19.0476% | -178.2609% | -3.5714% | -6.8966% | 21.2121% | 12.5% | -9.0909% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.1433 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PACB
2026-02-23 18:16:51
Pacific Biosciences of California (PacBio) is investigating how different technologies influence the understanding derived from DNA sequencing. In a "Beyond the Bench" episode, Dr. Kiss likened sequencing to playing a vinyl record, emphasizing the critical role of technology choice for extracting valuable DNA information. This perspective encourages professionals to assess barriers hindering deeper insights in their respective fields.
2026-02-23 11:12:23
Pacific Biosciences COO Mark Van Oene sold 184,897 shares on February 17, 2026, which is often seen as a negative signal for the company's future performance and could impact investor confidence and stock price volatility. This executive sell-off may also lead to changes in the company's shareholder structure and prompt a reassessment of its strategic direction. Wall Street analysts currently have a "Moderate Buy" rating on PACB stock, with an average price target of $2.40.
2026-02-22 15:40:25
PacBio and Berry Genomics have announced a collaboration to introduce a long-read desktop sequencing instrument to the clinical market in China. Building on an existing partnership, Berry Genomics will provide funding and guidance for the development of PacBio's first desktop platform and commit to purchasing at least 50 systems. This initiative aims to make high-accuracy HiFi sequencing more accessible to a broader range of laboratories across China by offering a smaller, more affordable instrument.
2026-02-22 02:47:49
PacBio announced the commercial shipment of its Revio long-read sequencing systems will begin on March 8, 2023. The Revio system offers significantly increased throughput and lower sequencing costs with high accuracy, enabling researchers to scale their genomic analyses. Major institutions like Baylor College of Medicine, Broad Institute, and Wellcome Sanger Institute are among the first customers, with some planning to use multiple systems to advance human, plant, and animal genomics research globally.
2026-02-20 15:03:05
Michele Farmer, Chief Accounting Officer at Pacific Biosciences of California, Inc. (NASDAQ:PACB), sold 50,167 shares of common stock for approximately $79,855 on February 17 and 18, 2026. These sales were primarily to cover tax obligations from vested restricted stock units. Despite the sale, Farmer still directly owns 219,092 shares, and the company recently reported stronger-than-expected earnings for Q4 2025.
2026-02-20 01:56:53
Chief Operating Officer Mark Van Oene sold 184,897 shares of Pacific Biosciences of California (NASDAQ:PACB) for a total of $294,318 to cover tax obligations. Following these transactions, he directly owns 1,742,638 shares. This sale comes after the company reported better-than-expected Q4 2025 financial results, with a smaller loss per share and higher revenue than anticipated.
